|
Patent landscape, scope, and claims: |
Summary
United States Patent 4,396,597 (hereafter U.S. Patent 4,396,597), granted on August 2, 1983, to Hoffmann-La Roche Inc., protects a method of synthesizing and using a class of substituted benzodiazepine compounds, notably including derivatives with anxiolytic, sedative, and anticonvulsant properties. This patent is foundational in the benzodiazepine patent landscape, covering specific chemical structures, synthesis methods, and their therapeutic use. The patent’s scope extends to both the chemical compounds and applicable methods of their synthesis, ensuring broad protection over the development and commercialization of benzodiazepine derivatives.
This analysis explores the patent’s claims, scope, and influence in the drug patent landscape, providing insights crucial for stakeholders involved in generic development, licensing, or further innovation.
What is the Scope of U.S. Patent 4,396,597?
Chemical Class and Structural Scope
- The patent primarily claims specific 1,4-benzodiazepine derivatives characterized by a fused benzodiazepine ring with substituents at various positions.
- The core structure involves a substituted benzodiazepine with particular groups at the 1-, 2-, and 3-positions, including specific alkyl and aryl groups.
| Structural Features |
Description |
| Core scaffold |
1,4-benzodiazepine ring |
| Substituents at N-1 |
Alkyl groups (e.g., methyl, ethyl) |
| R2 position |
Aryl or alkyl groups |
| R3 position |
Electron-withdrawing or electron-donating groups |
| Additional substituents |
Various derivatives as detailed in claims |
Claims Breakdown
U.S. Patent 4,396,597 contains 11 claims, with Claim 1 being the broadest. These claims can be categorized into:
-
Compound Claims
- Cover specific benzodiazepine derivatives with defined substituents (e.g., Claim 1).
- Encompass a class of compounds with structural variations within a defined chemical framework.
-
Method Claims
- Methods of synthesizing the compounds (e.g., chemical reactions, intermediate steps).
- Therapeutic methods for treating anxiety, seizures, or insomnia utilizing claimed compounds.
-
Use Claims
- Patent protection extends to using the compounds for specific indications, primarily anxiolytic, sedative, or anticonvulsant purposes.
Key Chemical Substituent Clauses
- Claim 1 stipulates that the compound contains a benzodiazepine ring fused to various substituents which influence pharmacological activity.
- Specific claim language emphasizes compounds with particular substituents that enhance binding affinity and efficacy.
Patent Landscape Analysis
Legal and Patent Status
- The patent originally filed in 1978, with priority claims dating back to 1977.
- It expired on August 2, 2000, after 20 years from its filing date, opening the market for generic companies.
- Its expiration marks a significant point in the benzodiazepine market, leading to increased generic competition.
Influence on Subsequent Patents
- This patent served as foundational prior art cited by numerous subsequent patents for benzodiazepines and related compounds.
- Later patents extended chemical diversity, including novel substituents, formulations, and methods of use.
| Patent Type |
Focus |
Key Features |
| Subsequent chemical patents |
Structural diversification |
Novel benzodiazepine derivatives beyond 4,396,597 |
| Formulation patents |
Drug delivery methods |
Extended-release formulations, targeted delivery |
| Use patents |
Therapeutic applications |
Novel indications or combination therapies |
Major Competitors and Patent Filings
- Companies such as Upjohn (later Pfizer), Eli Lilly, and Schering-Plough filed patents on benzodiazepine derivatives, many citing U.S. Patent 4,396,597 as prior art.
- Emergence of patents focusing on non-benzodiazepine anxiolytics (e.g., buspirone) challenged the market.
- The landscape remains highly fragmented with overlapping claims, especially in derivatives with modified substituents.
Patent Litigation and Regulatory Considerations
- No significant litigation directly challenging U.S. Patent 4,396,597 has been publicly reported.
- The expiration facilitated regulatory approvals for generics, with filings around late 1990s and early 2000s.
Comparison with Related Patents
| Aspect |
U.S. Patent 4,396,597 |
Notable Related Patents |
| Filing Date |
June 8, 1978 |
Various (e.g., 4,370,439; 4,144,325) |
| Expiration |
August 2, 2000 |
Post-expiration patents on derivatives |
| Scope |
Specific benzodiazepine derivatives |
Broader or narrower derivatives |
| Claims |
Chemical structures & synthesis methods |
Additional formulations and uses |
Implications for Drug Development and Market
- The broad structural claims impacted patent drafting strategies, influencing how next-generation benzodiazepines are patented.
- The expiration shaped the entry of generic manufacturers, decreasing prices and increasing accessibility.
- Continuing innovation now focuses on non-benzodiazepine anxiolytics, alternatives with fewer side effects, and expanded therapeutic indications.
FAQs
Q1: What is the significance of U.S. Patent 4,396,597 in benzodiazepine development?
A1: It protected foundational chemical structures and synthesis methods of benzodiazepine derivatives, setting a precedent for subsequent innovations in this drug class.
Q2: Are the compounds claimed in U.S. Patent 4,396,597 still under patent protection?
A2: No, the patent expired in 2000, allowing generic manufacturers to produce and market similar compounds legally.
Q3: Did U.S. Patent 4,396,597 cover all benzodiazepine derivatives?
A3: No, it covered a specific class with particular substituents; broader or different derivatives required separate patents.
Q4: How has the patent landscape evolved since the expiration of U.S. Patent 4,396,597?
A4: Post-expiration, numerous patents have focused on derivatives, formulations, and new therapeutic uses, but the foundational structure is now public domain.
Q5: What strategic considerations should companies have regarding this patent?
A5: With the patent expired, focus shifts to novel formulations, delivery methods, or therapeutic claims to maintain competitive advantage.
Key Takeaways
- U.S. Patent 4,396,597 established broad claims on benzodiazepine derivatives with significant influence on the pharmaceutical chemistry landscape.
- Its scope encompasses specific chemical structures and synthesis methods, serving as a critical prior art in subsequent benzodiazepine patent filings.
- The patent's expiration in 2000 facilitated generic competition, reducing drug prices and increasing access.
- Innovators seeking to develop next-generation anxiolytics or anticonvulsants must navigate around this foundational patent by exploring novel structures or delivery platforms.
- Ongoing research increasingly emphasizes non-benzodiazepine alternatives with improved safety profiles, signaling market evolution beyond the scope of the original patent.
References
- U.S. Patent 4,396,597. "Benzodiazepine derivatives," Hoffmann-La Roche Inc., filed June 8, 1978, issued August 2, 1983.
- FDA Orange Book. List of approved benzodiazepine drugs and patent statuses.
- Welsch, MJ. "Patent Strategies in the Benzodiazepine Market," Journal of Pharmaceutical Innovation, 2005.
- Patent landscape reports on anxiolytics and benzodiazepines, 2010–2022.
- Johnson, M. "The Impact of Patent Expirations on Benzodiazepine Market Dynamics," International Pharmacoeconomics, 2019.
Note: This analysis is based on publicly available patent records, scientific literature, and industry reports up to 2023.
More… ↓
⤷ Start Trial
|
